Bayer, Regeneron Link For Eye Disease | Chemical & Engineering News
Volume 84 Issue 43 | p. 29
Issue Date: October 23, 2006

Bayer, Regeneron Link For Eye Disease

Department: Business

Bayer HealthCare and Regeneron Pharmaceuticals will collaborate to develop Regeneron's VEGF Trap-Eye for the treatment of eye disease. VEGF Trap-Eye is a protein that binds to or "traps" vascular endothelial growth factor, thought to play a critical role in eye disease. The drug is currently in Phase I and II clinical trials. Regeneron will get $75 million up front from Bayer and will be eligible for milestone payments of up to $245 million. The firms will jointly commercialize VEGF Trap-Eye outside the U.S.; Regeneron has all U.S. rights.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment